Skip to Main Content
DownloadHi-Res Photo

James Boyer, MD, FACEP

Ensign Professor of Medicine (Digestive Diseases); Emeritus Director, Yale Liver Center

Contact Information

James Boyer, MD, FACEP

Mailing Address

  • Yale School of Medicine

    Department of Medicine (Digestive Diseases), PO Box 208019

    New Haven, CT 06520-8019

    United States

Yale Liver Center
Download CV
Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Our laboratory has a long standing interest in the basic physiology of bile formation and the pathophysiologic mechanisms underlying mechanisms of cholestasis. Bile formation is one of the unique functions of the liver and is impaired in many forms of cholestatic liver injury. Our early studies established that the hepatocyte is a polarized secretory cell where transport mechanisms are organized on plasma membrane domains like a classic epithelium (Physiologic Reviews 60:303-326, 1980). This concept has led to the identification and characterization of a number of membrane transport proteins both at the functional level and through molecular cloning techniques that determine the secretion of bile (Physiologic Reviews 83:633-671, 2003). Current studies focus on mechanisms by which bile acids injure the liver in cholestatic liver diseases and determinations of new approaches for therapy of these diseases including the use of bile derived organoids and cell lines for drug discovery. Trainees utilize a variety of fundamental techniques ranging from general cell biologic and molecular biologic procedures, as well as organoid development from human liver and bile, to advanced morphologic approaches including fluorescent and confocal scanning microscopy. This research has been supported by NIH grants, core facilities provided by an NIH Liver Center and donations.

Specialized Terms: Membrane transport; Bile formation; Cholestasis; Nuclear receptors; Bile acids; Organoids;, exosomes; Membrane targeting; Jaundice; Autoimmune hepatitis; Primary Biliary Cholangitis; Sclerosing Cholangitis; Hepatic drug toxicity.

Extensive Research Description

Dr. Boyer's laboratory has pioneered in establishing the molecular and cellular basis for bile secretory function of the liver. In the late 1970’s, he established that the sodium pump was localized to the basolateral membrane of the hepatocytes. This work placed the hepatocyte as a more typical polarized epithelium and allowed paradigms that were developed in other polarized epithelia to be applied to the liver. For example, this finding allowed Dr. Boyer’s lab to purify canalicular membranes away from the basolateral domain and thus introduce the use of membrane vesicle preparations for studying transport activity. The development of in-vivo models for studying bile secretory functions (the hepatocytes couplet and the isolated bile duct unit) initially from rats and later from mice was also a major technical advance for the field. These models have been widely used by many investigators for the study of hepatobiliary transport function in live cell preparations without the confounding effects of blood flow inherent in intact or isolated perfused rat livers. These models also permited the localization of specific functions to either hepatocytes or cholangiocytes. His laboratory was also the first to demonstrate and annunciate the concept that hepatobiliary transporters undergo adaptive regulation in response to cholestatic liver injury both in liver and in kidney. This is an area of investigation subsequently widely pursued by many laboratories . This work has led to studies of the role of nuclear receptors in the regulation of transporter expression and a search for novel therapies directed to stimulation of this adaptive response.The discovery of a novel heteromeric organic solute transporter, Ost alpha-Ost beta in the liver of the marine skate by Dr. Boyer and his colleague, Ned Ballatori has led serendipitoiusly to the finding that this is the missing link the basolateral ideal transporter)in the enterohepatic circulation of bile salts. This important discovery came from work at the Mt Desert Island biological Laboratory in Maine where Dr. Boyer and colleagues have pursued seasonal research using a comparative animal model approach with marine vertebrates for nearly 4 decades. Currently his lab is studying the mechanisms by which bile acids activate an inflammatory casade in hepatocytes and cholangiocytes and have pioneered in the development of human bile derived organoids to study the mechansimf of the disease, Primary Sclerosing Cholangitis. The impact of this body of work has been recognized by the Adolf Windaus Prize presented by the Falk Foundation in 1988, the Distinguished Achievement Award from the American Gastroenterology Association in 1989, the Distinguished Achievement Award from the American Association for the Study of Liver Disease in 1998 and the Distinguished Scientific Achievement Award from the American Liver Association in 1999. In 2020, he received the European Association of the Study of the Liver's prestigious International Recognition Award.

  1. Mechansims of bile acid induced inflammatory injury and the role of innate immunity in cholestasis
  2. The use of biliary organoids for drug discovery in cholestatic liver diseases.

Coauthors

Research Interests

Bile; Cholestasis; Digestive System Diseases; Jaundice; Liver; Organoids; Cholangitis, Sclerosing

Selected Publications

  • Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.Cai SY, Yu D, Soroka CJ, Wang J, Boyer JL. Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis. Journal Of Hepatology 2021, 74: 550-559. PMID: 33039404, PMCID: PMC7897288, DOI: 10.1016/j.jhep.2020.09.035.
  • The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiology.Li B, Cai SY, Boyer JL. The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiology. Biochimica Et Biophysica Acta. Molecular Basis Of Disease 2021, 1867: 166085. PMID: 33497820, DOI: 10.1016/j.bbadis.2021.166085.
  • Bile formation and secretion: An update.Boyer JL, Soroka CJ. Bile formation and secretion: An update. Journal Of Hepatology 2021, 75: 190-201. PMID: 33617926, DOI: 10.1016/j.jhep.2021.02.011.
  • Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology (Baltimore, Md.) 2021, 73: 2099-2109. PMID: 33713486, PMCID: PMC8250536, DOI: 10.1002/hep.31797.
  • Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine.Soroka CJ, Roberts SJ, Boyer JL, Assis DN. Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. Seminars In Liver Disease 2021, 41: 206-212. PMID: 33957696, DOI: 10.1055/s-0041-1728663.
  • The role of bile acids in cholestatic liver injury.Cai SY, Boyer JL. The role of bile acids in cholestatic liver injury. Annals Of Translational Medicine 2021, 9: 737. PMID: 33987435, PMCID: PMC8106037, DOI: 10.21037/atm-20-5110.
  • Obituary for Roberto J. Groszmann-The Father of Portal Hypertension.Shah V, Iwakiri Y, Boyer JL. Obituary for Roberto J. Groszmann-The Father of Portal Hypertension. Hepatology (Baltimore, Md.) 2021, 74: 1724-1726. PMID: 34105802, DOI: 10.1002/hep.31996.
  • In Memoriam: Peter J. Meier (1947-2021).Stieger B, Boyer JL. In Memoriam: Peter J. Meier (1947-2021). Journal Of Hepatology 2021 PMID: 34332756, DOI: 10.1016/j.jhep.2021.06.039.
  • Paul David Berk, editor extraordinaire and bilirubinologist.Boyer JL, Wolkoff AW. Paul David Berk, editor extraordinaire and bilirubinologist. Hepatology (Baltimore, Md.) 2022, 75: 236-237. PMID: 34403150, DOI: 10.1002/hep.32104.
  • Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases.Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.) 2022, 75: 1012-1013. PMID: 34431119, DOI: 10.1002/hep.32117.
  • Letter to the Editor: On the mechanisms of biliary flux.Javitt NB, Boyer JL. Letter to the Editor: On the mechanisms of biliary flux. Hepatology (Baltimore, Md.) 2022, 75: 492-493. PMID: 34543482, DOI: 10.1002/hep.32167.
  • Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.Gallucci GM, Trottier J, Hemme C, Assis DN, Boyer JL, Barbier O, Ghonem NS. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. Hepatology Communications 2021, 5: 2035-2051. PMID: 34558841, PMCID: PMC8631103, DOI: 10.1002/hep4.1787.
  • Organic Solute Transporter Alpha Deficiency: A Disorder With Cholestasis, Liver Fibrosis, and Congenital Diarrhea.Gao E, Cheema H, Waheed N, Mushtaq I, Erden N, Nelson-Williams C, Jain D, Soroka CJ, Boyer JL, Khalil Y, Clayton PT, Mistry PK, Lifton RP, Vilarinho S. Organic Solute Transporter Alpha Deficiency: A Disorder With Cholestasis, Liver Fibrosis, and Congenital Diarrhea. Hepatology (Baltimore, Md.) 2020, 71: 1879-1882. PMID: 31863603, PMCID: PMC8577800, DOI: 10.1002/hep.31087.
  • Inflammasome Is Activated in the Liver of Cholestatic Patients and Aggravates Hepatic Injury in Bile Duct-Ligated Mouse.Cai SY, Ge M, Mennone A, Hoque R, Ouyang X, Boyer JL. Inflammasome Is Activated in the Liver of Cholestatic Patients and Aggravates Hepatic Injury in Bile Duct-Ligated Mouse. Cellular And Molecular Gastroenterology And Hepatology 2020, 9: 679-688. PMID: 31887435, PMCID: PMC7160576, DOI: 10.1016/j.jcmgh.2019.12.008.
  • Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology And Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.
  • Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.) 2019, 69: 394-419. PMID: 30070375, DOI: 10.1002/hep.30145.
  • Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile.Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. Hepatology (Baltimore, Md.) 2019, 70: 871-882. PMID: 30561836, DOI: 10.1002/hep.30470.
  • Bile Infarcts: New Insights Into the Pathogenesis of Obstructive Cholestasis.Cai SY, Boyer JL. Bile Infarcts: New Insights Into the Pathogenesis of Obstructive Cholestasis. Hepatology (Baltimore, Md.) 2019, 69: 473-475. PMID: 30251326, DOI: 10.1002/hep.30291.
  • Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies.Soroka CJ, Assis DN, Boyer JL. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. Methods In Molecular Biology (Clifton, N.J.) 2019, 1981: 363-372. PMID: 31016667, DOI: 10.1007/978-1-4939-9420-5_24.
  • Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents.Yu D, Cai SY, Mennone A, Vig P, Boyer JL. Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver International : Official Journal Of The International Association For The Study Of The Liver 2018, 38: 1128-1138. PMID: 29356312, PMCID: PMC6032984, DOI: 10.1111/liv.13698.
  • OSTα-OSTβ Guards the Ileal Enterocyte From the Accumulation of Toxic Levels of Bile Acids.Boyer JL. OSTα-OSTβ Guards the Ileal Enterocyte From the Accumulation of Toxic Levels of Bile Acids. Cellular And Molecular Gastroenterology And Hepatology 2018, 5: 649-650. PMID: 29713669, PMCID: PMC5924743, DOI: 10.1016/j.jcmgh.2018.01.015.
  • Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis.Pan Q, Zhang X, Zhang L, Cheng Y, Zhao N, Li F, Zhou X, Chen S, Li J, Xu S, Huang D, Chen Y, Li L, Wang H, Chen W, Cai SY, Boyer JL, Chai J. Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis. Gastroenterology 2018, 155: 1578-1592.e16. PMID: 30063921, PMCID: PMC6221191, DOI: 10.1053/j.gastro.2018.07.031.
  • Maintaining a Vibrant and Productive Laboratory as a Senior Investigator.Boyer JL. Maintaining a Vibrant and Productive Laboratory as a Senior Investigator. Cellular And Molecular Gastroenterology And Hepatology 2017, 4: 299-300. PMID: 28840184, PMCID: PMC5560913, DOI: 10.1016/j.jcmgh.2017.04.008.
  • CFTR-associated ligand is a negative regulator of Mrp2 expression.Li M, Soroka CJ, Harry K, Boyer JL. CFTR-associated ligand is a negative regulator of Mrp2 expression. American Journal Of Physiology. Cell Physiology 2017, 312: C40-C46. PMID: 27834195, PMCID: PMC5283898, DOI: 10.1152/ajpcell.00100.2016.
  • Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/MCG.0000000000000591.
  • Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury.Cai SY, Boyer JL. Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. Inflammation And Cell Signaling 2017, 4 PMID: 28804737, PMCID: PMC5553904.
  • Mechanisms of bile acid mediated inflammation in the liver.Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver. Molecular Aspects Of Medicine 2017, 56: 45-53. PMID: 28606651, PMCID: PMC5662014, DOI: 10.1016/j.mam.2017.06.001.
  • Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response.Cai SY, Ouyang X, Chen Y, Soroka CJ, Wang J, Mennone A, Wang Y, Mehal WZ, Jain D, Boyer JL. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight 2017, 2: e90780. PMID: 28289714, PMCID: PMC5333973, DOI: 10.1172/jci.insight.90780.
  • Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis.Kulkarni SR, Soroka CJ, Hagey LR, Boyer JL. Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis. Hepatology (Baltimore, Md.) 2016, 64: 2151-2164. PMID: 27639250, PMCID: PMC5115990, DOI: 10.1002/hep.28826.
  • A Novel Di-Leucine Motif at the N-Terminus of Human Organic Solute Transporter Beta Is Essential for Protein Association and Membrane Localization.Xu S, Soroka CJ, Sun AQ, Backos DS, Mennone A, Suchy FJ, Boyer JL. A Novel Di-Leucine Motif at the N-Terminus of Human Organic Solute Transporter Beta Is Essential for Protein Association and Membrane Localization. PloS One 2016, 11: e0158269. PMID: 27351185, PMCID: PMC4924846, DOI: 10.1371/journal.pone.0158269.
  • Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis.Chai J, Cai SY, Liu X, Lian W, Chen S, Zhang L, Feng X, Cheng Y, He X, He Y, Chen L, Wang R, Wang H, Boyer JL, Chen W. Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis. Journal Of Hepatology 2015, 63: 1440-8. PMID: 26212029, PMCID: PMC4686151, DOI: 10.1016/j.jhep.2015.07.016.
  • The origins of hepatobiliary and gastrointestinal physiology.Boyer JL. The origins of hepatobiliary and gastrointestinal physiology. Hepatology (Baltimore, Md.) 2015, 61: 1452-4. PMID: 25677183, PMCID: PMC4447183, DOI: 10.1002/hep.27737.
  • Fibrates and cholestasis.Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology (Baltimore, Md.) 2015, 62: 635-43. PMID: 25678132, PMCID: PMC4515188, DOI: 10.1002/hep.27744.
  • Na(+) /H(+) exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury.Li M, Mennone A, Soroka CJ, Hagey LR, Ouyang X, Weinman EJ, Boyer JL. Na(+) /H(+) exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury. Hepatology (Baltimore, Md.) 2015, 62: 1227-36. PMID: 26108984, PMCID: PMC4589453, DOI: 10.1002/hep.27956.
  • Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations.Soroka CJ, Boyer JL. Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations. Molecular Aspects Of Medicine 2014, 37: 3-14. PMID: 23685087, PMCID: PMC3784619, DOI: 10.1016/j.mam.2013.05.001.
  • The role of macrophage migration inhibitory factor in autoimmune liver disease.Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic-Paterson DJ, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology (Baltimore, Md.) 2014, 59: 580-91. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.
  • Bile formation and secretion.Boyer JL. Bile formation and secretion. Comprehensive Physiology 2013, 3: 1035-78. PMID: 23897680, PMCID: PMC4091928, DOI: 10.1002/cphy.c120027.
  • Adult sea lamprey tolerates biliary atresia by altering bile salt composition and renal excretion.Cai SY, Lionarons DA, Hagey L, Soroka CJ, Mennone A, Boyer JL. Adult sea lamprey tolerates biliary atresia by altering bile salt composition and renal excretion. Hepatology (Baltimore, Md.) 2013, 57: 2418-26. PMID: 23175353, PMCID: PMC3604052, DOI: 10.1002/hep.26161.
  • A C-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis.Lam P, Xu S, Soroka CJ, Boyer JL. A C-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis. Hepatology (Baltimore, Md.) 2012, 55: 1901-11. PMID: 22161577, PMCID: PMC3319652, DOI: 10.1002/hep.25523.
  • Ostα depletion protects liver from oral bile acid load.Soroka CJ, Velazquez H, Mennone A, Ballatori N, Boyer JL. Ostα depletion protects liver from oral bile acid load. American Journal Of Physiology. Gastrointestinal And Liver Physiology 2011, 301: G574-9. PMID: 21719738, PMCID: PMC3174539, DOI: 10.1152/ajpgi.00141.2011.
  • Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.He H, Mennone A, Boyer JL, Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology (Baltimore, Md.) 2011, 53: 548-57. PMID: 21274875, PMCID: PMC3069505, DOI: 10.1002/hep.24047.
  • Drug-induced cholestasis.Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology (Baltimore, Md.) 2011, 53: 1377-87. PMID: 21480339, PMCID: PMC3089004, DOI: 10.1002/hep.24229.
  • ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained.Cai SY, Gautam S, Nguyen T, Soroka CJ, Rahner C, Boyer JL. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology 2009, 136: 1060-9. PMID: 19027009, PMCID: PMC3439851, DOI: 10.1053/j.gastro.2008.10.025.
  • It's all about bile.Boyer JL. It's all about bile. Hepatology (Baltimore, Md.) 2009, 49: 711-23. PMID: 19242972, DOI: 10.1002/hep.22719.
  • A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis.Pan Q, Luo G, Qu J, Chen S, Zhang X, Zhao N, Ding J, Yang H, Li M, Li L, Cheng Y, Li X, Xie Q, Li Q, Zhou X, Zou H, Fan S, Zou L, Liu W, Deng G, Cai SY, Boyer JL, Chai J. A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis. EMBO Molecular Medicine 2021, 13: e14563. PMID: 34585848, PMCID: PMC8573601, DOI: 10.15252/emmm.202114563.
  • Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations.Cai SY, Wang L, Ballatori N, Boyer JL. Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations. American Journal Of Physiology. Gastrointestinal And Liver Physiology 2001, 281: G316-22. PMID: 11447010, DOI: 10.1152/ajpgi.2001.281.2.G316.
  • Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, Assis DN, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver International : Official Journal Of The International Association For The Study Of The Liver 2022, 42: 607-614. PMID: 34846800, DOI: 10.1111/liv.15121.
  • Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium.Goldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer JL, Assis D, Bowlus C. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology And Hepatology : The Official Clinical Practice Journal Of The American Gastroenterological Association 2018, 16: 591-593. PMID: 29102704, PMCID: PMC5860952, DOI: 10.1016/j.cgh.2017.10.028.
  • Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis.Alrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports (Online) 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.

Clinical Trials

ConditionsStudy Title
Diseases of the Digestive System - Liver; Diseases of the Digestive System - Pancreas; Diseases of the Digestive System - Small Intestines, Large Intestines & RectumStudy of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)
Hepatitis; HIV/AIDS; Immune System; Infectious DiseasesScreening In Anticipation of Future Research
Edit Profile